Equities

Sichuan Biokin Pharmaceutical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Sichuan Biokin Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)289.40
  • Today's Change-2.60 / -0.89%
  • Shares traded1.39m
  • 1 Year change+51.28%
  • Beta--
Data delayed at least 15 minutes, as of Feb 12 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Sichuan Biokin Pharmaceutical Co Ltd is a China-based company mainly engaged in the drug research and development, production and marketing. The Company is mainly engaged in innovative biologics business as well as generics and traditional Chinese medicine business. The Company's main products include anesthesia drugs, parenteral nutrition drugs, anti-Infective drugs, Chaihuang granule and others. The Company distributes its products within the domestic market and to overseas markets.

  • Revenue in CNY (TTM)2.23bn
  • Net income in CNY-852.38m
  • Incorporated2006
  • Employees2.52k
  • Location
    Sichuan Biokin Pharmaceutical Co LtdNo. 1, Building 1, No. 161, Baili Road,Chengdu Strait LiangAn Science and TechnCHENGDU 611130ChinaCHN
  • Phone+86 2 885321013
  • Fax+86 2 885320270
  • Websitehttp://www.baili-pharm.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zhangzhou Pientzhng Phrmctcl Co Ltd9.78bn2.42bn101.11bn2.84k41.796.99--10.344.014.0116.2123.990.55151.1511.113,444,842.0013.6018.5316.5823.2436.9845.9124.6528.422.12--0.065842.267.2513.526.4216.7274.8129.36
Torrent Pharmaceuticals Ltd9.33bn1.63bn104.61bn16.11k64.1616.2546.6111.2163.2363.23361.86249.640.80051.266.177,604,203.0013.999.5420.0814.7275.6972.5617.4714.140.835214.670.250461.097.357.7215.3914.488.5130.36
CSPC Pharmaceutical Group Ltd26.22bn4.06bn106.78bn19.27k26.12--57.024.070.40120.40122.59--------1,385,753.00--14.64--19.4966.2372.5015.5419.11------41.10-7.765.59-26.313.114.7621.28
Moderna Inc15.43bn-21.54bn109.41bn5.80k--1.70--7.09-8.05-8.055.7623.860.15982.191.71384,827.60-22.3113.72-25.9118.7663.4976.34-139.6123.743.73--0.00610.00-52.75121.8624.46--101.61--
Sino Biopharmaceutical Ltd30.58bn3.90bn113.31bn23.06k27.953.2413.943.710.24430.24271.912.110.43172.833.981,418,383.009.5612.1618.5220.9181.7780.7522.1526.501.28--0.207127.1910.183.563.93-7.01-7.916.66
Swedish Orphan Biovitrum AB (publ)21.93bn371.29m113.33bn1.89k314.773.7436.845.171.301.3081.42109.120.39531.285.1114,956,040.000.66633.920.83375.0478.8977.841.6910.910.5859.770.23360.008.5013.10-87.70-31.82-3.93--
Sichuan Biokin Pharmaceutical Co Ltd2.23bn-852.38m120.56bn2.52k--16.81--54.16-2.14-2.145.5417.370.23091.442.31883,003.90-8.8427.12-11.3147.5989.1586.86-38.2929.035.23--0.34460.00936.3137.00575.02243.6931.86--
Viatris Inc97.65bn-25.52bn128.43bn32.00k--1.23--1.32-3.10-3.1011.9613.130.34172.094.90441,387.50-8.93-0.1756-10.89-0.209639.3640.66-26.13-0.57680.7932.790.4868---4.465.09-1,259.42---3.10--
Divi's Laboratories Ltd7.86bn1.89bn129.18bn18.30k68.34--57.8816.4493.4593.45388.82--------5,636,066.00--15.81--17.3361.6555.9024.0425.82------35.1919.3111.6536.949.743.9813.40
Roivant Sciences Ltd92.02m-5.59bn132.60bn750.00--4.46--1,441.08-1.17-1.170.01936.020.0024----17,746.67-18.265.89-20.806.9891.2190.39-7,558.42639.97----0.000.00-11.19-15.56-111.69---1.32--
Incyte Corp35.54bn8.89bn135.99bn2.84k15.433.8014.253.836.406.4025.6126.040.82914.335.481,807,750.0020.7511.3427.8314.3893.2693.9225.0316.483.25--0.00670.0021.2214.033,844.96---20.67--
Innovent Biologics Inc11.43bn1.13bn137.56bn6.19k117.429.0984.9112.040.76350.76357.779.870.52051.807.392,283,453.005.16-8.716.52-10.7385.6984.749.91-24.842.39--0.1898--51.8255.1790.79--35.02--
Shionogi & Co Ltd20.99bn8.79bn140.21bn4.96k15.261.9614.406.68228.94228.94546.701,779.330.28690.86482.7693,915,640.0011.9812.1713.1313.7484.5084.9141.7838.305.21--0.014827.870.73255.625.196.8834.6612.30
United Therapeutics Corp21.63bn8.79bn141.64bn1.31k18.023.1015.136.5526.4126.4164.94153.610.43232.219.782,397,242.0017.5713.6119.4814.8488.5990.7940.6537.816.07--0.000.0023.6314.7121.35--24.11--
Data as of Feb 12 2026. Currency figures normalised to Sichuan Biokin Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

35.48%Per cent of shares held by top holders
HolderShares% Held
E Fund Management Co., Ltd.as of 30 Jun 20256.80m6.61%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 20255.90m5.73%
China Asset Management Co., Ltd.as of 30 Jun 20255.76m5.60%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 20254.31m4.19%
China Universal Asset Management Co., Ltd.as of 30 Jun 20254.29m4.17%
GF Fund Management Co., Ltd.as of 30 Jun 20253.22m3.13%
Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 20252.03m1.97%
ICBC UBS Asset Management Co. Ltd.as of 30 Jun 20251.76m1.71%
China Merchants Fund Management Co., Ltd.as of 30 Jun 20251.39m1.35%
Bank of China Investment Management Co., Ltd.as of 30 Jun 20251.05m1.02%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.